Connect your AI

OptimizeRx OPRX Debt Instrument Of Prepayments Premium

Other financials

Income statement

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

Market cap$107.34M-50.4%

Enterprise value$110.88M-51.4%

P/E15.7×—

P/S1×-1.1×

Profitability

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept oprx:DebtInstrumentOfPrepaymentsPremium.

The official record: OptimizeRx’s 10-K, filed March 20, 2025, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's debt instrument of prepayments premium.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is OptimizeRx's debt instrument of prepayments premium?: OptimizeRx (OPRX) reported debt instrument of prepayments premium of 3% in Q4 2024.